Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2015-04-02 Share Issue/Capital Cha…
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science FR
Share Issue/Capital Change Classification · 95% confidence The document is titled 'INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL' (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references Article 221-1 and 223-16 of the AMF General Regulation (French financial regulator). It provides a table showing the total number of shares and voting rights as of a specific date (March 31, 2015). This content directly relates to the structure of the capital and voting rights, which aligns best with the 'Declaration of Voting Results & Voting Rights Announcements' (DVA) category, as it is a formal disclosure of voting rights count, even if it's a monthly update rather than post-meeting results. It is not a full financial report (10-K, IR), nor a management change (MANG), nor a director's trade (DIRS).
2015-04-02 French
AB Science FR
Regulatory Filings Classification · 95% confidence The document is a press release from AB Science SA, dated March 20, 2015, announcing that its drug, masitinib, received Orphan Drug Designation from the US FDA for the treatment of Amyotrophic Lateral Sclerosis (ALS). This type of announcement, detailing a specific regulatory milestone (Orphan Drug Designation) and its implications (commercial exclusivity, funding opportunities), is a standard corporate communication. It is not a full Annual Report (10-K), an Interim Report (IR), a formal Audit Report (AR), or a transcript (CT). Since it is a specific announcement regarding regulatory progress and drug development, it fits best under the general category of Regulatory Filings (RNS) as a specific corporate update, although it could also be considered a type of Investor Presentation (IP) if it were a slide deck. Given the format is a press release detailing a regulatory event, RNS is the most appropriate general classification for non-standard, specific regulatory news, or it could be argued as a Capital/Financing Update (CAP) due to the mention of tax credits and funding, but the core subject is regulatory approval status. Given the options, RNS serves as the best fit for a specific, non-periodic regulatory news release that isn't a major financial filing or management change.
2015-03-20 French
AB Science FR
Regulatory Filings Classification · 95% confidence The document is an announcement from AB Science regarding the U.S. Food and Drug Administration (FDA) granting Orphan Drug designation for masitinib in the treatment of amyotrophic lateral sclerosis (ALS). This is a specific regulatory/clinical development update concerning a drug candidate, detailing benefits like marketing exclusivity and research grants. It is not a comprehensive annual report (10-K), a quarterly report (IR), an earnings release (ER), or a general management discussion (MDA). It is a specific announcement about a regulatory milestone related to a drug's development. Since there is no specific category for 'Drug Regulatory Milestone' or 'Clinical Update,' and it is a formal announcement of a significant event that impacts the company's operations and future prospects, it best fits under the general 'Regulatory Filings' (RNS) category as a miscellaneous, non-financial, specific regulatory announcement, or potentially 'LTR' if viewed as a legal/regulatory proceeding update, but RNS is the broader fit for non-standard announcements. Given the context of FDA action, RNS is the most appropriate fallback for a specific regulatory event not covered by other codes.
2015-03-20 English
AB Science FR
Capital/Financing Update Classification · 95% confidence The document is a short press release dated March 17, 2015, announcing that the company, AB Science, meets the eligibility criteria for the PEA-PME (a French equity savings plan for SMEs). It details the criteria (employee count, revenue/balance sheet size) and provides general company information. This is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). It is a specific corporate update regarding regulatory/listing eligibility, which fits best under a general regulatory announcement or a capital/financing update, although it is not strictly about raising capital. Given the nature of confirming eligibility for a specific financial product/status, it is a specific corporate action announcement. Since it doesn't fit perfectly into the defined categories like DIV, SHA, or CAP (which usually imply active fundraising or share changes), and it is a formal announcement of a status update, it leans towards a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) if PEA-PME eligibility is considered a financing mechanism update. However, since it is a specific regulatory status confirmation, RNS is the most appropriate fallback for non-standard announcements. Given the short length and announcement style, RNS is chosen over a more specific category.
2015-03-17 French
2015.02.28- nombre total de droits de vote et d'actions
Share Issue/Capital Change Classification · 95% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly Information Relating to the Total Number of Voting Rights and Shares Comprising the Share Capital). It explicitly references Article 221-1 and 223-16 of the AMF (Autorité des Marchés Financiers) General Regulation. It provides a table showing the total number of shares and voting rights as of a specific date (February 28, 2015). This type of mandatory monthly disclosure regarding the total number of shares and voting rights is a standard regulatory filing in France, often categorized under general regulatory announcements or specific share/capital change disclosures. Given the options, this is a specific regulatory disclosure about the capital structure and voting rights, which is not explicitly covered by DVA (Voting Results), SHA (Share Issue), or POS (Transaction in Own Shares). It is a routine regulatory update. Since it is a specific, recurring regulatory disclosure that doesn't fit the primary definitions (like 10-K, ER, IR), the most appropriate general regulatory category is RNS (Regulatory Filings), as it is a mandatory disclosure to the market regulator.
2015-03-05 French
AB Science FR
Regulatory Filings Classification · 95% confidence The document is a press release from AB Science SA, dated February 9, 2015, announcing a positive futility analysis result for its Phase 3 clinical trial of masitinib in Alzheimer's disease. It details the study status, previous Phase 2 results, scientific rationale, and concludes by announcing an upcoming web conference. This type of announcement, detailing clinical trial progress and results outside of a formal quarterly/annual report, is characteristic of an Earnings Release (ER) or a general press release related to operational/clinical updates. Since it focuses on key operational/clinical milestones rather than just financial figures (which would lean towards ER), and it is a formal announcement of a significant event, it fits best under the general category for corporate announcements or press releases that don't fit other specific categories. However, given the content is a major operational update (clinical trial success) and not a formal regulatory filing like a 10-K or a specific financial report like an IR, it is most closely aligned with an Earnings Release (ER) if it were quarterly results, or a Regulatory Filing (RNS) as a general announcement. Since it is a specific, material announcement about clinical progress, and not just a notice that a report is coming (RPA), RNS is the most appropriate fallback for a significant, non-financial-statement-focused press release. If 'ER' is interpreted broadly to include major operational updates, it could fit, but RNS covers general regulatory/material announcements well.
2015-02-10 French

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.